Posted by Michael Wonder on 07 Oct 2017
Leukaemia patients to get access to AbbVie’s Venclyxto via Cancer Drugs Fund
5 October 2017 - AbbVie has struck a deal with NICE to make its leukaemia drug Venclyxto available through the Cancer Drugs Fund.
The new treatment Venclyxto (venetoclax) is to be available to NHS patients in England with chronic lymphocytic leukaemia (CLL), the common form of adult leukaemia via the CDF while it accrues more cost-effectiveness data.
Venclyxto will be available to adults with difficult-to-treat types of chronic lymphocytic leukaemia – those patients without 17p deletion or TP53 mutation who have failed both chemo-immunotherapy and a B-cell receptor (BCR) inhibitor.
